RNS Hotlist with Zak Mir: CAP-XX, Eve, Genedrive, Mirriad, N4 Pharma, Nostra, Okyo, Seraphim. Symphony, TM1, Union Jack

All eyes are on Okyo (OKYO) as the biotechnology company announced that the patent entitled "Methods and Systems for Designing and/or Characterizing Soluble Lipidated has been issued by the United States Patent and Trademark Office as U.S. Patent No. 11,254,720. This patent contains key claims covering OK-101 to treat neuropathic pain.

Making it big in the US is always a key milestone for a minnow and Symphony Environmental (SYM), the sustainable plastics group, announced the commencement of a two year exclusive US supply contract for their d2w biodegradable plastics technology in nutritional supplement bottles and the US launch with Better Earth LLC of a new bottle for nutritional-supplements using d2w.

Also looking west is Mirriad (MIRI), the in-content advertising company, as it revealed a new partnership in the strategically important North American market and an update on strong campaign metrics illustrating significant audience reach advantages of in-content advertising verusus traditional advertising. Mirriad has signed a partnership agreement with Canada's largest TV and digital media conglomerate, presumably to the delight of Justin Trudeau.

eve Sleep (EVE), the direct to consumer sleep wellness brand operating in the UK, Ireland and France announced a new retail partnership with DFS, a furniture retailer in the United Kingdom, where the Winter Sale is apparently now on. In fact, a sale is always on. Initially the partnership will cover the dfs.co.uk website, which receives an average 2.71m unique visitors per month – apparently all looking to buy at sale prices.

Technology Minerals (TM1), the battery metals group, announced an update on the OEL Share Purchase Agreement. OEL's wholly-owned subsidiary, Technology Minerals Cameroon Limited applied for five exploration permits in Cameroon. The company has now received copies of all permits concerned and has instructed Cameroon legal counsel to verify the validity of the permits.

There were bumper interims from CAP-XX (CPX), the designer and manufacturer of supercapacitors, for the half-year ended 31 December 2021. Total revenue was up 14% on corresponding half-year, Product sales were up 40% driven by DMF/DMT product lines and IoT markets and the Sales order book at 31/12/21 was more than 40% higher than 31/12/20. The sales pipeline is now in excess of $50 million p.a. Interest from global multinational companies is increasing, especially for DMH, DMF and DMT products. The company has also signed a sourcing Agreement with Continental Automotive GmbH, to provide CAP-XX DMT220 prismatic supercaps.

It would appear that Nostra Terra (NTOG), the international oil & gas exploration and production company is now producing enough to supply your local Shell garage on a consistent basis.  It revealed a 37% increase in company revenue ($767,000 Q4 vs $558,000 Q3), a 23% increase in net daily production (118 bopd Q4 vs 96 bopd Q3), a 10% increase in oil sales price per bbl ( $70.52 Q4 vs $63.57 Q3). NTOG is drilling a new development well (Fouke 2), at Pine Mills (NTOG 32.5% Working Interest), with the Initiation of field infrastructure work at Pine Mills to increase handling capacity and reliability. Planning is underway for up to 3 new wells in the Permian Basin by year end 2022.

Seraphim Space Investment Trust (SSIT), the world's first listed SpaceTech fund, appears to be rocketing. It announced maiden interim results covering the period from incorporation on 14 May 2021 to 31 December 2021. Net asset value (NAV) was up 43.2% to £250.6m. The company has liquid resources of £70.0m (27.9% of NAV) at 31 December 2021. £135m of capital deployed since IPO, in line with expectations and has a strong investment pipeline.

Just in time for the end of the pandemic, genedrive (GDR), the near patient molecular diagnostics company, provided an update on the progress being made on the Genedrive® COV19-ID kit. The company said progress since CE marking is as expected in terms of timeline and a focus on specific use cases. It is “pleased” with the distributor agreements it has contracted to date and expects to expand to additional countries in due course. It added that while UK government policy has changed, opportunities are continuing in other markets that are taking a different approach with regards to testing.

N4 Pharma (N4P), the specialist pharmaceutical company, announced its audited results for the year ended 31 December 2021. The company said that as a result of the positive findings from the evaluation studies looking at the potential of Nuvec® as a nano-carrier of a DNA plasmid expressing TNFalpha, which demonstrated a significant inhibition of tumour growth derived from a human cell line, the company has commenced work with Medicines Discovery Catapult to extend the observations to allow us to identify suitable loads to add to Nuvec® to take to clinic.

Union Jack Oil (UJO) a UK focused onshore hydrocarbon production, development and exploration company, said that it intends to allow the payment of a dividend or implement a share repurchase programme. It also intends to maintain a strong balance sheet which is debt free throughout the oil price cycle and continue to invest in growth projects held, which include Wressle, West Newton, Keddington and Biscathorpe.